Back to results
US 2014/0179665 A1Published application
Hepatitis b antiviral agents
AssigneeNovira Therapeutics, Inc.
InventorsGeorge D. Hartman, Osvaldo A. Flores
Life of this patent
Estimating the term…
Abstract
The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
Claims22
A compound of Formula IV:
- or pharmaceutically acceptable salts thereof;
- wherein
- R4 is H or C1-C6 alkyl;
- wherein each R5 is independently selected at each occurrence from the group consisting of CH3, C1-C6 alkoxy, halo, —CN, —NO2, -(L)m-SR9, -(L)m-S(═O)R9, -(L)m-S(═O)2R9, -(L)m-NHS(═O)2R9, -(L)m-C(═O)R9, -(L)m-OC(═O)R9, -(L)mCO2R8, -(L)m-OCO2R8, -(L)m-N(R8)2, -(L)m-C(═O)N(R8)2, -(L)m-OC(═O)N(R8)2, -(L)m-NHC(═O)NH(R8), -(L)m-NHC(═O)R9, -(L)m-NHC(═O)OR9, -(L)m-C(OH)(R8)2, -(L)mC(NH2)(R8)2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl and —C1-C6 trihaloalkyl;
- L is independently, at each occurrence, a bivalent radical selected from —(C1-C3 alkylene)-, —(C3-C7 cycloalkylene)-, —(C1-C3 alkylene)m-O—(C1-C3 alkylene)m-, or —(C1-C3 alkylene)m-NH—(C1-C3 alkylene)m-;
- each R8 is independently, at each occurrence, H, C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R2;
- R9 is C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 0-5 substituents selected from R2;
- R10 is OH, C1-C6 alkyl, C1-C6 alkyl-OH, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
- R11 is a bond or C1-C3 alkylene, wherein the C1-C3 alkylene is optionally substituted with 1-3 substituents selected from R2;
- R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, —C1-C6 heteroalkyl, and C(O) —C1-C6 alkyl;
- w is 0, 1 or 2;
- each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4;
- each occurrence of y is independently selected from the group consisting of 1, 2, and 3;
- each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3;
- each occurrence of m is independently 0, 1 or 2.
12 more elements
11-28. (canceled)
(canceled)
33-37. (canceled)
43-46. (canceled)
Dependencies are inferred from the claim text.